Stock CURAS CURASIGHT A/S
Add to a list
To use this feature you must be a member
Log inSign up

All News Curasight A/S

Equities

CURAS

DK0061295797

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 18:00:00 2024-05-02 EDT 		5-day change 1st Jan Change
9.96 DKK +0.20% Intraday chart for Curasight A/S +9.45% -43.89%
04-16 Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients CI
04-12 Curasight A/S Announces Board Changes CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
BioStock: Curasight gets green light from EMA in phase II prostate cancer trial
AQ
Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients
AQ
Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients
CI
Curasight announces change in the Board of Directors
AQ
Curasight A/S Announces Board Changes
CI
BioStock: Curasight cancels rights issue and evaluates alternative financing
AQ
Curasight not to proceed with rights issue; evaluating alternative financing opportunities
AQ
Notice of Annual General Meeting 2024
AQ
The subscription period in Curasight's rights issue begins today
AQ
Curasight publishes information memorandum in connection with forthcoming rights issue
AQ
Annual Report for the fiscal year 2023
AQ
Year-end report October - December 2023
AQ
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
BioStock: Curasight to accelerate therapeutic strategy by DKK 51.2 million capital raise
AQ
Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy
PR
Curasight resolves on a rights issue of up to DKK 51.2 million to accelerate its therapeutic strategy
AQ
Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company
AQ
Curasight A/S Announces Acceleration of Therapeutic Strategy to Strengthen Position as A Radiopharmaceutical Theranostic Company
CI
BioStock: Curasight gets first milestone payment from Curium
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CURAS Stock
  4. News Curasight A/S
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW